MedPath

Alaxia SAS

Alaxia SAS logo
🇫🇷France
Ownership
Private
Established
2008-01-01
Employees
-
Market Cap
-
Website
http://www.alaxia-pharma.eu

Clinical Trials

3

Active:0
Completed:0

Trial Phases

2 Phases

Phase 1:1
Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 2
2 (66.7%)
Phase 1
1 (33.3%)

Dose Finding Study of STR-324

Phase 2
Conditions
Pain, Acute
Interventions
First Posted Date
2020-10-12
Last Posted Date
2021-07-13
Lead Sponsor
Alaxia SAS
Target Recruit Count
118
Registration Number
NCT04582786
Locations
🇳🇱

Leiden University Medical Center, Leiden, Netherlands

Dose Escalation Study of ALX-009 in Healthy Men and Cystic Fibrosis (CF) and Non-CF Bronchiectasis Patients

Phase 1
Terminated
Conditions
Cystic Fibrosis
Bronchiectasis
Interventions
Drug: OSCN-
Drug: bLF
Drug: Placebo
First Posted Date
2015-11-06
Last Posted Date
2022-02-03
Lead Sponsor
Alaxia SAS
Target Recruit Count
92
Registration Number
NCT02598999
Locations
🇫🇷

Eurofins Optimed, Grenoble, France

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.